Navigating the Complexities of Adding Rare Disease Products to Your Company’s Portfolio

Rare disease products, biopharmaceutical development, commercialization, market access, patient identification, payer contract strategy, value-based contracting, regulatory incentives, emerging technology.

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###

Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology

Revolutionizing Drug Discovery: The Evolution from Target-Selective Design to AI-Powered Polypharmacology

Drug Discovery, Target-Selective Design, AI-Enabled Polypharmacology, Machine Learning, Systems Biology, Multi-Target Drugs, Personalized Medicine.

Revolutionizing Protein Design: Nabla Bio Secures $26M for AI-Driven Pharmaceutical Solutions

Nabla Bio, genAI protein design, funding, pharmaceutical partners, biotechnology, protein engineering, drug discovery, artificial intelligence, healthcare innovation.